The Swedish BioFINDER Study
The BioFINDER studies are independent and non-overlapping studies that have been initiated with the overarching aims to discover key mechanisms in Alzheimer’s disease, Parkinson’s disease and other neurodegenerative disorders. These studies are designed to develop early and accurate diagnostic tests, identify novel treatment targets and help to understand the links between different pathologies and clinical symptoms.
News articles
Blood Tests: Not Just for the Impaired?
In memory clinics and in research cohorts, immunoassays for plasma markers can now distinguish people who have Alzheimer’s disease...
Read more...Looking Good: Immunoassays for Blood Markers
For years, scientists have been working toward blood tests for Alzheimer’s disease that could be used routinely in clinical...
Read more...
Recent key publications
- 10 April, 2025
Plasma phospho-tau217 for Alzheimer’s disease diagnosis in primary and secondary care using a fully automated platform
- 31 March, 2025
Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer’s disease
- 28 March, 2025
Plasma p-tau217 and tau-PET predict future cognitive decline among cognitively unimpaired individuals: implications for clinical trials
- 4 March, 2025
Machine learning prediction of tau‐PET in Alzheimer’s disease using plasma, MRI, and clinical data
X posts
🚨New publication in @NatureAging🚨
Co-led between @MontoliuGaya and @gesalbla.
We measured several tau peptides in blood and assess their different relationships with Alzheimer’s disease stages.
🧵
Plasma tau biomarkers for biological staging of Alzheimer’s disease
Nature Aging - Montoliu-Gaya, Salvadó et al. develop a blood-based model using tau biomarkers measured in a single ...
www.nature.com
4⃣In summary, we have developed a biomarker-based staging model using plasma tau biomarkers and validated in TRIAD. We believe these findings will enhance the application of blood tau biomarkers, improving patient management in both clinical trials and routine clinical practice.
Thanks to all coauthors: @JosephTherr , @NicholasAshton, @andrealessa, @NiklasMattsson4, @SebastianPalmqv, @EStomrud, @pedrorosaneto, and @OskarHansson9
And those not on X.
🚨New paper alert! This study led by @SEMastenbroek aims to make detection of α-synuclein pathology in the brain more time- and cost-effective. Out now in Nature Communications! 🔗 Full article: https://www.nature.com/articles/s41467-025-62458-7.epdf?sharing_token=fJsM7nw6WLFQSLEmJtlXiNRgN0jAjWel9jnR3ZoTv0MDVkWnZxGsgtCMfY18v2PG-JBJvKhRsSwlFHbyWcVEhi_UdJDYtyqFZKb0-1LE-RJuxLzTxso4Wsn_ZLSgyRQKvtbjLPDfKEVHUrWMYnYD648e1kcTBiQcj_tBKohdF6g%3D
A thread🧵👇
6/🧵Taken together, we present an accurate two-step approach for predicting LBP in the brain using a smell test followed by CSF SAA testing in smell-test positive individuals. This could minimize costs, reduce patient burden, and improve the known underdiagnosis of DLB and PD.
A huge thanks to all authors and collaborators who made this work possible! @OskarHansson9 @LECollij @_JakeVogel_ @SebastianPalmqv @FBarkhof @RikOssenkoppele and all not on X.
🚨Publication alert: This study led by @WuestefeldAnika aims to provide a more granular understanding of how tau pathology leads to specific cognitive decline in Alzheimer's disease. 🧠 Out now in Alzheimer’s & Dementia! Read it here:
🧵👇
Tau, atrophy, and domain‐specific cognitive impairment in typical Alzheimer's disease
INTRODUCTION A granular understanding of the mechanisms linking tau pathology to cognitive decline in Alzheimer's diseas...
doi.org
7⃣This suggests that region-specific atrophy functions as one pathway of tau-induced cognitive subdomain impairments. Yet, large portions of variance remains unexplained, highlighting the need for investigating other mechanistic links.🔬
8⃣A huge thank you to all authors as well as the #ADNI study participants who made this work possible. Your contributions are vital for advancing our understanding of the disease and contribute to #ENDALZ.